Format

Send to

Choose Destination
Curr Cancer Drug Targets. 2018 Jun 27. doi: 10.2174/1568009618666180628101059. [Epub ahead of print]

Targeting Glycosylation Aberrations To Improve The Efficiency Of Cancer Phototherapy.

Author information

1
Universite de Toulouse, CRCT, INSERM UMR 1037, 2 Avenue Hubert Curien, 31037 Toulouse. France.
2
Universite de Toulouse, Pharma-Dev, Institut de Recherche pour le Developpement (IRD) UMR 152, Faculte des Sciences Pharmaceutiques, F-31062 Toulouse cedex 09. France.

Abstract

The use of photodynamic therapy in cancer still remains limited, partly because of the lack of photosensitizer (PS) specificity for the cancerous tissues. Various molecular tools are available to increase PS efficiency by targeting the cancer cell molecular alterations. The most strategies use the protein-protein interactions, e.g. monoclonal antibodies directed toward tumor antigens, such as HER2 or EGFR. An alternative could be the targeting of the tumor glycosylation aberrations, e.g. T/Tn antigens that are truncated O-glycans over-expressed in numerous tumors. Thus, to achieve an effective targeting, PS can be conjugated to molecules that specifically recognize the O-glycosylation aberrations at the cancer cell surface.

KEYWORDS:

O-glycosylation; PhotoDynamic Therapy (PDT); PhotoSensitizer (PS); T/Tn antigens; aptamers; cancer cells; lectins; metastasis.; monoclonal Antibodies (moAbs)

Supplemental Content

Full text links

Icon for Bentham Science Publishers Ltd.
Loading ...
Support Center